Medical Affairs

Publications

External links to publications from the adrabetadex – historically known as 2-hydroxypropyl-β-cyclodextrin or VTS-270 – clinical development program and expanded access program.

Clinical Study
A Phase 1/2 Open Label Nonrandomized Clinical Trial of Intravenous 2-Hydroxypropyl-β-Cyclodextrin for Acute Liver Disease in Infants With Niemann-Pick C1

September 2021

Molecular Genetics and Metabolism Reports
Clinical Study
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1​

June 2019

CNS Drugs
Clinical Study
Intrathecal 2-Hydroxypropyl-β-Cyclodextrin Decreases Neurological Disease Progression in Niemann-Pick Disease, Type C1: A Non-Randomised, Open-Label, Phase 1–2 Trial

October 2017

Lancet

Contact Beren Medical

If you have additional questions related to information provided on this website or other medical inquiries, please contact the Beren Medical Affairs team at medinfo@berentx.com.

The information provided on this website is provided by the Beren Therapeutics P.B.C. (“Beren”) Medical Affairs team for healthcare professionals in the US. It is designed to provide self-service access to medical information and medical affairs content about Beren products, pipeline, and therapeutic areas of interest including clinical data, research developments, congress materials, and publications. Certain materials such as posters and presentations presented in this website are a result of Beren-sponsored research and are not intended to be a comprehensive overview of all information and materials presented at a particular congress. The website is intended to provide scientifically balanced information and educational resources and may include information related to products or indications that have not been approved by the US Food and Drug Administration. The information provided is not intended as medical advice and does not replace independent medical judgement. By searching this website, you confirm the unsolicited nature of your inquiry. Please confirm that you agree and that you are a registered healthcare professional registered to practice in the US.

Are you a US healthcare provider?

No